LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Scope Fluidics’ Microfluidic Antimicrobial Susceptibility System Obtains European CE IVD Marking Approval

By LabMedica International staff writers
Posted on 29 Oct 2021
Print article
Image: BacterOMIC system (Photo courtesy of Scope Fluidics)
Image: BacterOMIC system (Photo courtesy of Scope Fluidics)

Scope Fluidics’ (Warsaw, Poland) BacterOMIC microfluidic antimicrobial susceptibility system has received a European CE marking certificate for in vitro diagnostic devices, which approves it for use on the European Union market.

The BacterOMIC system allows for the identification in a single test of the effectiveness of a range of 20 antibiotics that are used in the treatment of, among others, infections of the respiratory tract, blood, urinary tract, or skin, caused by the Enterobacterales; Pseudomonas; Acinetobacter, Staphylococcus bacteria. The system makes it possible to assess the treatment effectiveness for the following antibiotics, all in one test: amoxicillin, cefuroxime, cefazolin, tobramycin, amikacin, azithromycin, ceftazidime, ceftazidime with avibactam, ciprofloxacin, clindamycin, ceftriaxone, cefotaxime, cefepime, moxifloxacin, norfloxacin, ofloxacin, piperacillin, piperacillin with tazobactam, trimethoprim, trimethoprim with sulfamethoxazole.

The modern diagnostic device has undergone clinical tests of the first diagnostic panel. The tests confirmed the functionality of the BacterOMIC system in diagnosing the drug susceptibility of bacteria causing a number of infections, including in the respiratory system, blood, urinary tract and skin. During specialized tests carried out in independent clinical centers, the system achieved over 90% compliance in the drug susceptibility assessment for 20 antibiotics which were assigned to one of the two resistance categories: resistant/susceptible. The company plans to expand the system with more antibiotics in order to make full use of the system’s diagnostic capabilities.

“BacterOMIC is a system with a very large market potential, which has a chance to revolutionize antibiotic treatment,” said Marcin Izydorzak, Vice President and one of the founders of Scope Fluidics. “Today, the needs of doctors and their patients in this area are enormous. Experts estimate that the market for automated antimicrobial susceptibility testing is worth approximately USD1 billion annually. Clinical tests have proven the efficiency of the BacterOMIC system, which ultimately might be able to test all clinically significant antibiotics in one test.”

“BacterOMIC is an exceptional solution on a world scale, and ultimately it is intended to allow us to check up to 640 bacteria cultivation conditions in one test,” added Dr. Seweryn Bajer-Borstyn, head of the BacterOMIC project in the Scope Fluidics Group. “This will translate into the possibility of creating a single test to cover most clinically used antibiotics. We are happy that our work on all the aspects of the system were confirmed in the clinical tests of the first BacterOMIC diagnostic panel.”

Related Links:
Scope Fluidics 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more